Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue ...

DURHAM, N.C.and SEATTLE, Jan. 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...

Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, today announced the launch of Ncyte® Microglia, a groundbreaking tool to advance research in neurodegenerative ...

This important study offers insights into the function and connectivity patterns of a relatively unknown afferent input from the endopiriform to the CA1 subfield of the ventral hippocampus, suggesting ...

2025 年 1 月 13 日，庆应义塾大学医学院的研究人员在 Cell 子刊 Cell Reports Medicine 上发表了题为：A first-in-human clinical study of an allogenic iPSC-derived corneal endothelial cell substitute transplantation for bullous ...

2025 年 1 月 13 日，庆应义塾大学医学院的研究人员在 Cell 子刊 Cell Reports Medicine 上发表了题为：A first-in-human clinical study of an allogenic iPSC-derived corneal ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...